The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Abstract
Metal based therapeutics are a precious class of drugs in oncology research that include examples of theranostic drugs, which are active in both diagnostic, specifically imaging, and therapeutics applications. Ruthenium compounds have shown selective bioactivity and the ability to overcome the resistance that platinum-based therapeutics face, making them effective oncotherapeutic competitors in rational drug invention approaches. The development of antineoplastic ruthenium therapeutics is of particular interest because ruthenium containing complexes NAMI-A, KP1019, and KP1339 entered clinical trials and DW1/2 is in preclinical levels. The very robust, conformationally rigid organometallic Ru(II) compound DW1/2 is a protein kinase inhibitor and presents new Ru(II) compound designs as anticancer agents. Over the recent years, numerous strategies have been used to encapsulate Ru(II) derived compounds in a nanomaterial system, improving their targeting and delivery into neoplastic cells. A new photodynamic therapy based Ru(II) therapeutic, TLD-1433, has also entered clinical trials. Ru(II)-based compounds can also be photosensitizers for photodynamic therapy, which has proven to be an effective new, alternative, and noninvasive oncotherapy modality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., & Peng, Q. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.889 · Cited by 4,716
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Valastyan, S., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.09.024 · Cited by 4,011
Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?
Balasubramanian, S., Hurley, L. H., & Neidle, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3428 · Cited by 1,692
DNA and its associated processes as targets for cancer therapy
Hurley, L. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc749 · Cited by 1,349
Targeting Apoptosis Pathways in Cancer Therapy
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.3.178 · Cited by 1,330
Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention
Tomasetti, C., Li, L., & Vogelstein, B. (2017) · Science · doi:10.1126/science.aaf9011 · Cited by 1,113
The global burden of cancer: priorities for prevention
Thun, M. J., DeLancey, J. O., Center, M. M., Jemal, A., & Ward, E. M. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp263 · Cited by 1,091
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
Hartinger, C. G., & Dyson, P. J. (2009) · Chem. Soc. Rev. · doi:10.1039/b707077m · Cited by 985
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
Morris, R. E., Aird, R. E., del Socorro Murdoch, P., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010051m · Cited by 787
Gill, M. R., & Thomas, J. A. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15299a · Cited by 747
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Trondl, R., Heffeter, P., Kowol, C. R., Jakupec, M. A., Berger, W., & Keppler, B. K. (2014) · Chem. Sci. · doi:10.1039/c3sc53243g · Cited by 675
Areneruthenium complexes as anticancer agents
Süß‐Fink, G. (2009) · Dalton Transactions · doi:10.1039/b916860p · Cited by 652
Heinemann, F., Karges, J., & Gasser, G. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00180 · Cited by 611
Combination of Ru(ii) complexes and light: new frontiers in cancer therapy
Mari, C., Pierroz, V., Ferrari, S., & Gasser, G. (2015) · Chemical Science · doi:10.1039/c4sc03759f · Cited by 570
Ruthenium Complexes as Anticancer Agents
Kostova, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360941 · Cited by 566
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine
Farrer, N. J., Salassa, L., & Sadler, P. J. (2009) · Dalton Transactions · doi:10.1039/b917753a · Cited by 496
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Ruthenium Antimetastatic Agents
Alessio, E., Mestroni, G., Bergamo, A., & Sava, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387421 · Cited by 479
Methods to Explore Cellular Uptake of Ruthenium Complexes
Puckett, C. A., & Barton, J. K. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0677564 · Cited by 467
Huang, H., Yu, B., Zhang, P., Huang, J., Chen, Y., Gasser, G., Ji, L., & Chao, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507800 · Cited by 449
Poynton, F. E., Bright, S. A., Blasco, S., Williams, D. C., Kelly, J. M., & Gunnlaugsson, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00680b · Cited by 421
Alessio, E. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600986 · Cited by 388
Leijen, S., Burgers, S. A., Baas, P., Pluim, D., Tibben, M., van Werkhoven, E., Alessio, E., Sava, G., Beijnen, J. H., & Schellens, J. H. M. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0179-1 · Cited by 374
Adhireksan, Z., Davey, G. E., Campomanes, P., Groessl, M., Clavel, C. M., Yu, H., Nazarov, A. A., Yeo, C. H. F., Ang, W. H., Dröge, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4462 · Cited by 297
Targeting DNA damage response in cancer therapy
Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 294
Shi, G., Monro, S., Hennigar, R., Colpitts, J., Fong, J., Kasimova, K., Yin, H., DeCoste, R., Spencer, C., Chamberlain, L., et al. (2015) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.04.012 · Cited by 279
Exploring biologically relevant chemical space with metal complexes
Meggers, E. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.05.013 · Cited by 274
Casini, A., Gabbiani, C., Sorrentino, F., Rigobello, M. P., Bindoli, A., Geldbach, T. J., Marrone, A., Re, N., Hartinger, C. G., Dyson, P. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006678 · Cited by 270
Chatterjee, S., Kundu, S., Bhattacharyya, A., Hartinger, C. G., & Dyson, P. J. (2008) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-008-0400-9 · Cited by 258
Tan, C., Lai, S., Wu, S., Hu, S., Zhou, L., Chen, Y., Wang, M., Zhu, Y., Lian, W., Peng, W., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1009296 · Cited by 244
Ruthenium Polypyridyl Complexes That Induce Mitochondria-Mediated Apoptosis in Cancer Cells
Chen, T., Liu, Y., Zheng, W.-J., Liu, J., & Wong, Y.-S. (2010) · Inorganic Chemistry · doi:10.1021/ic100277w · Cited by 241
Ruthenium Half‐Sandwich Complexes Bound to Protein Kinase Pim‐1
Debreczeni, J. É., Bullock, A. N., Atilla, G. E., Williams, D. S., Bregman, H., Knapp, S., & Meggers, E. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200503468 · Cited by 234
Levina, A., Crans, D. C., & Lay, P. A. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.01.002 · Cited by 233
Self-citationTargeting Nucleus DNA with a Cyclometalated Dipyridophenazineruthenium(II) Complex
Huang, H., Zhang, P., Yu, B., Chen, Y., Wang, J., Ji, L., & Chao, H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501095r · Cited by 230
Recent Developments in the Field of Anticancer Platinum Complexes
Galanski, M. S. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206777442287 · Cited by 223
Organometallic Compounds: An Opportunity for Chemical Biology?
Patra, M., & Gasser, G. (2012) · ChemBioChem · doi:10.1002/cbic.201200159 · Cited by 213
A Red‐Light‐Activated Ruthenium‐Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells
Lameijer, L. N., Ernst, D., Hopkins, S. L., Meijer, M. S., Askes, S. H. C., Le Dévédec, S. E., & Bonnet, S. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201703890 · Cited by 212
Notaro, A., & Gasser, G. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00356k · Cited by 210
Meng, X., Leyva, M. L., Jenny, M., Gross, I., Benosman, S., Fricker, B., Harlepp, S., Hébraud, P., Boos, A., Wlosik, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4408 · Cited by 208
Protein kinase biochemistry and drug discovery
Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 201
Targeting Large Kinase Active Site with Rigid, Bulky Octahedral Ruthenium Complexes
Maksimoska, J., Feng, L., Harms, K., Yi, C., Kissil, J., Marmorstein, R., & Meggers, E. (2008) · Journal of the American Chemical Society · doi:10.1021/ja805555a · Cited by 200
Development of Ruthenium Antitumor Drugs that Overcome Multidrug Resistance Mechanisms
Vock, C. A., Ang, W. H., Scolaro, C., Phillips, A. D., Lagopoulos, L., Juillerat-Jeanneret, L., Sava, G., Scopelliti, R., & Dyson, P. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070039f · Cited by 185
Liu, T., Zeng, L., Jiang, W., Fu, Y., Zheng, W., & Chen, T. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.01.009 · Cited by 179
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
Heffeter, P., Böck, K., Atil, B., Reza Hoda, M. A., Körner, W., Bartel, C., Jungwirth, U., Keppler, B. K., Micksche, M., Berger, W., et al. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0642-1 · Cited by 173
Frei, A., Rubbiani, R., Tubafard, S., Blacque, O., Anstaett, P., Felgenträger, A., Maisch, T., Spiccia, L., & Gasser, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500566f · Cited by 171
Bregman, H. S., Carroll, P. J., & Meggers, E. (2005) · Journal of the American Chemical Society · doi:10.1021/ja055523r · Cited by 165
Zhang, P., Huang, H., Huang, J., Chen, H., Wang, J., Qiu, K., Zhao, D., Ji, L., & Chao, H. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b07510 · Cited by 163
Mechanisms of platinum drug resistance
Ohmichi, M., Hayakawa, J., Tasaka, K., Kurachi, H., & Murata, Y. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.002 · Cited by 159
Shen, J., Kim, H.-C., Wolfram, J., Mu, C., Zhang, W., Liu, H., Xie, Y., Mai, J., Zhang, H., Li, Z., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b00132 · Cited by 147
Nanoparticles: synthesis and applications
Nam, N. H., & Luong, N. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102814-8.00008-1 · Cited by 141
Docetaxel Nanotechnology in Anticancer Therapy
Zhao, P., & Astruc, D. (2012) · ChemMedChem · doi:10.1002/cmdc.201200052 · Cited by 136
Nováková, O., Kašpárková, J., Bursová, V., Hofr, C., Vojtíšková, M., Chen, H., Sadler, P. J., & Brabec, V. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.11.008 · Cited by 136
An ethylene-glycol decorated ruthenium(ii) complex for two-photon photodynamic therapy
Boca, S., Four, M., Bonne, A., van der Sanden, B. P. J., Aştilean, S., Baldeck, P. L., & Lemercier, G. (2009) · Chemical Communications · doi:10.1039/b907143a · Cited by 127
Hess, J., Huang, H., Kaiser, A., Pierroz, V., Blacque, O., Chao, H., & Gasser, G. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701392 · Cited by 127
Sun, D., Liu, Y., Yu, Q., Qin, X., Yang, L., Zhou, Y., Chen, L., & Liu, J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.007 · Cited by 126
Chen, Z., Qin, Q., Qin, J.-L., Zhou, J., Li, Y., Li, N., Liu, Y., & Liang, H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00444 · Cited by 125
Sun, D., Liu, Y., Yu, Q., Zhou, Y., Zhang, R., Chen, X., Hong, A., & Liu, J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.031 · Cited by 125
Modulating the Anticancer Activity of Ruthenium(II)–Arene Complexes
Clavel, C. M., Păunescu, E., Nowak-Sliwinska, P. M., Griffioen, A. W., Scopelliti, R., & Dyson, P. J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501655t · Cited by 119
New Ruthenium(II)–Letrozole Complexes as Anticancer Therapeutics
Castonguay, A., Doucet, C., Juhas, M., & Maysinger, D. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301103y · Cited by 118
Berndsen, R. H., Weiss, A., Abdul, U. K., Wong, T. J., Meraldi, P., Griffioen, A. W., Dyson, P. J., & Nowak-Sliwinska, P. M. (2017) · Scientific Reports · doi:10.1038/srep43005 · Cited by 113
Zeng, L., Chen, Y., Liu, J., Huang, H., Guan, R., Ji, L., & Chao, H. (2016) · Scientific Reports · doi:10.1038/srep19449 · Cited by 112
Frik, M., Martínez, A., Elie, B. T., Gonzalo, Ó., de Mingo, D. R., Sanaú, M., Sánchez‐Delgado, R. A., Sadhukha, T., Prabha, S., Ramos, J. W., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5012337 · Cited by 106
Arene–Ruthenium(II) Acylpyrazolonato Complexes: Apoptosis-Promoting Effects on Human Cancer Cells
Pettinari, R., Pettinari, C., Marchetti, F., Skelton, B. W., WHITE, A. H., Bonfili, L., Cuccioloni, M., Mozzicafreddo, M., Cecarini, V., Angeletti, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500458c · Cited by 99
Wan, D., Tang, B., Wang, Y.-J., Guo, B., Yin, H., Yi, Q.-Y., & Liu, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.066 · Cited by 98
Luo, Z., Yu, L., Yang, F., Zhao, Z., Yu, B., Lai, H., Wong, K., Ngai, S. M., Zheng, W., & Chen, T. (2014) · Metallomics · doi:10.1039/c4mt00044g · Cited by 97
Hayward, R. L., Schornagel, Q. C., Tente, R., Macpherson, J. S., Aird, R. E., Guichard, S. M., Habtemariam, A., Sadler, P. J., & Jodrell, D. I. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0932-9 · Cited by 95
Cloonan, S. M., Elmes, R. B. P., Erby, M., Bright, S. A., Poynton, F. E., Nolan, D. P., Quinn, S. J., Gunnlaugsson, T., & Williams, D. C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00451 · Cited by 93
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
Heffeter, P., Atil, B., Kryeziu, K., Groza, D., Koellensperger, G., Körner, W., Jungwirth, U., Mohr, T. T., Keppler, B. K., & Berger, W. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.018 · Cited by 92
Wang, N., Feng, Y., Zeng, L., Zhao, Z., & Chen, T. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b03739 · Cited by 91
Seršen, S., Kljun, J., Kryeziu, K., Panchuk, R. R., Alte, B., Körner, W., Heffeter, P., Berger, W., & Turel, I. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00288 · Cited by 87
Doucette, K. K., Hassell, K. N., & Crans, D. C. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.09.013 · Cited by 86
Self-citationRuthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage
Zamora, A., Denning, C. A., Heidary, D. K., Wachter, E., Nease, L. A., Ruiz, J., & Glazer, E. C. (2017) · Dalton Transactions · doi:10.1039/c6dt04405k · Cited by 86
Cytoxicity and Apoptotic Mechanism of Ruthenium(II) Amino Acid Complexes in Sarcoma-180 Tumor Cells
de Lima, A. P., Pereira, F. C., Almeida, M., Mello-Andrade, F., Pires, W. C., Pinto, T. M., Delella, F. K., Felisbino, S. L., Moreno, V., Batista, A. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105865 · Cited by 83
Huang, X., Chen, G., Pan, J., Chen, X., Huang, N., Wang, X., & Liu, J. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01122e · Cited by 83
Platinum Anticancer Drugs and Photochemotherapeutic Agents: Recent Advances and Future Developments
Shaili, E. (2014) · Science Progress · doi:10.3184/003685014x13904811808460 · Cited by 81
Montani, M., Pazmay, G. V. B., Hysi, A., Lupidi, G., Pettinari, R., Gambini, V., Tilio, M., Marchetti, F., Pettinari, C., Ferraro, S., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.032 · Cited by 79
Popolin, C. P., Reis, J. P. B., Becceneri, A. B., Graminha, A. E., Almeida, M., Corrêa, R. S., Colina–Vegas, L., Ellena, J., Batista, A. A., & Cominetti, M. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183275 · Cited by 79
Illuminating cytochrome P450 binding: Ru( ii )-caged inhibitors of CYP17A1
Li, A., Yadav, R., White, J. K., Herroon, M. K., Callahan, B. P., Podgorski, I., Turró, C., Scott, E. E., & Kodanko, J. J. (2017) · Chemical Communications · doi:10.1039/c7cc01459g · Cited by 77
Li, G., Chen, Y., Wang, J., Wu, J., Gasser, G., Ji, L., & Chao, H. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.06.014 · Cited by 71
Irace, C., Misso, G., Capuozzo, A., Piccolo, M., Riccardi, C., Luchini, A., Caraglia, M., Paduano, L., Montesarchio, D., & Santamaria, R. (2017) · Scientific Reports · doi:10.1038/srep45236 · Cited by 68
Synthesis, Anticancer Activity, and Genome Profiling of Thiazolo Arene Ruthenium Complexes
Grozav, A., Bălăcescu, O., Bălăcescu, L., Cheminel, T., Berindan‐Neagoe, I., & Therrien, B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00855 · Cited by 67
Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes
Carter, R., Westhorpe, A., Romero, M., Habtemariam, A., Gallevo, C., Bark, Y., Menezes, N., Sadler, P. J., & Sharma, R. (2016) · Scientific Reports · doi:10.1038/srep20596 · Cited by 63
Kamatchi, T. S., Chitrapriya, N., Kim, S. K., Fronczek, F. R., & Natarajan, K. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.11.024 · Cited by 61
Havrylyuk, D., Heidary, D. K., Nease, L. A., Parkin, S., & Glazer, E. C. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201601450 · Cited by 55
Čanović, P. P., Simović, A. R., Radisavljević, S., Bratsos, I., Demitri, N., Mitrović, M. M., Zelen, I., & Bugarčić, Ž. D. (2017) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-017-1479-7 · Cited by 54
Selective Ru(II)/lawsone complexes inhibiting tumor cell growth by apoptosis
de Oliveira, K. M., Liany, L.-D., Corrêa, R. S., Deflon, V. M., Cominetti, M. R., & Batista, A. A. (2017) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2017.08.019 · Cited by 54
Foxon, S. P., Green, C., Walker, M. G., Wragg, A. B., Adams, H., Weinstein, J. A., Parker, S., Meijer, A. J. H. M., & Thomas, J. A. (2011) · Inorganic Chemistry · doi:10.1021/ic201914h · Cited by 53
Artner, C., Holtkamp, H. U., Hartinger, C. G., & Meier, S. M. (2017) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2017.07.010 · Cited by 50
Thota, S., & Crans, D. C. (2017) · Wiley eBooks · doi:10.1002/9783527807093 · Cited by 49
Self-citationPhoto-induced DNA cleavage and cytotoxicity of a ruthenium(II) arene anticancer complex
Brabec, V., Prachařová, J., Štěpánková, J., Sadler, P. J., & Kašpárková, J. (2015) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2015.12.029 · Cited by 47
Chen, Y., Lei, W., Jiang, G., Hou, Y., Li, C., Zhang, B., Zhou, Q., & Wang, X. (2014) · Dalton Transactions · doi:10.1039/c4dt01755b · Cited by 46
Kumar, P., Dasari, S., & Patra, A. K. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.076 · Cited by 46
Biersack, B., Zoldáková, M., Effenberger, K. E., & Schobert, R. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.01.040 · Cited by 45
Spoerlein-Guettler, C., Mahal, K., Schobert, R., & Biersack, B. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.04.020 · Cited by 45
Lightening up Ruthenium Complexes to Fight Cancer?
Mari, C., & Gasser, G. (2015) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2015.176 · Cited by 41
Lemercier, G., Bonne, A., Four, M., & Daku, L. M. L. (2008) · Comptes Rendus Chimie · doi:10.1016/j.crci.2007.11.012 · Cited by 33
Ratanaphan, A., Nhukeaw, T., Hongthong, K., & Dyson, P. J. (2017) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520616666160404110953 · Cited by 33
Photolabile ruthenium complexes to cage and release a highly cytotoxic anticancer agent
Wei, J.-H., & Renfrew, A. K. (2017) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2017.11.018 · Cited by 29
Shi, S., Xie, T., Yao, T., Wang, C., Geng, X., Yang, D., Han, L., & Ji, L. (2009) · Polyhedron · doi:10.1016/j.poly.2009.02.035 · Cited by 27
Lai, S.-H., Li, W., Yao, J., Han, B.-J., Jiang, G., Zhang, C., Zeng, C.-C., & Liu, Y. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.02.015 · Cited by 26
Development of Arene Ruthenium Antitumor Complexes
Su, W., Tang, Z., & Li, P. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955751610160503003937 · Cited by 26
Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Zheng, K., Wu, Q., Wang, C., Tan, W., & Mei, W. (2017) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520616666160622085441 · Cited by 23
Chen, Y., Jiang, G., Zhou, Q., Zhang, Y., Li, K., Zheng, Y., Zhang, B., & Wang, X. (2016) · RSC Advances · doi:10.1039/c6ra03396b · Cited by 20
Crossing over to drug resistance
Livingston, D. M., & Silver, D. P. (2008) · Nature · doi:10.1038/4511066a · Cited by 19
Mello-Andrade, F., da Costa, W. L., Pires, W. C., Pereira, F. D. C., Cardoso, C. G., Júnior, R. D. S. L., Irusta, V. R. C., Carneiro, C. C., Reis, P. R. D. M., Castro, C. H., et al. (2017) · Tumor Biology · doi:10.1177/1010428317695933 · Cited by 16
Cited by
Alessio, E., & Messori, L. (2019) · Molecules · doi:10.3390/molecules24101995 · Cited by 385
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
NIR‐II Emissive Ru(II) Metallacycle Assisting Fluorescence Imaging and Cancer Therapy
Fan, Y., Li, C., Bai, S., Ma, X., Yang, J., Guan, X., & Sun, Y. (2022) · Small · doi:10.1002/smll.202201625 · Cited by 51
Metadata
- Authors
- Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-02-15
- Volume
- 61
- Issue
- 14
- Pages
- 5805-5821
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2785900358
- Cited by
- 476
- References
- 113
- FWCI
- 19.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.